Showing results (2131-2140 of 2,492) with videos related to

Sort By:
Pageof 250
The American Journal of Tropical Medicine and Hygiene|July 8, 2015
Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical TrialLuis Javier Martinez, Leyi Lin, Jason M Blaylock, et al.
Zootaxa|October 4, 2014
Nomenclatural and taxonomic problems related to the electronic publication of new nomina and nomenclatural acts in zoology, with brief comments on optical discs and on the situation in botanyAlain Dubois, Pierre-André Crochet, Edward C Dickinson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2021
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆J Niu, C Maurice-Dror, D H Lee, et al.
Neurourology and Urodynamics|June 23, 2020
High/low-volume center experience predicts outcome of AMS 800 in male stress incontinence: Results of a large middle European multicenter case seriesFabian Queissert, Tanja Hüsch, Alexander Kretschmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid TumorsJeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Future Oncology (London, England)|October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancerBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN StudyBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
JCI Insight|June 24, 2024
Histone demethylase JARID1C/KDM5C regulates Th17 cells by increasing IL-6 expression in diabetic plasmacytoid dendritic cellsChristopher O Audu, Sonya J Wolf, Amrita D Joshi, et al.
Free Radical Biology & Medicine|July 5, 2011
Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signalingImad Al Ghouleh, Nicholas K H Khoo, Ulla G Knaus, et al.
Pageof 250